ZyVersa Therapeutics, Inc. (ZVSA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Weston, FL, United States. El CEO actual es Stephen C. Glover.
ZVSA tiene fecha de IPO 2022-02-11, 7 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $1.55M.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
